Eli Lilly: An Update

|
About: Eli Lilly and Company (LLY), Includes: ABBV, BAYRY, BMY, BPMC, CELG, ELAN, LOXO, MRK, NVO, PFE
by: DoctoRx
This article is exclusive for subscribers.
DoctoRx
Special situations, growth at reasonable price, value, micro-cap
Summary

LLY has been in an uptrend, fueled by a good Q3 earnings report, an upbeat forecast for 2019, and strong top-line data from a key clinical trial.

This article reviews the clinical trial in detail and explains its potential importance.

Attention is also paid to LLY's GAAP versus non-GAAP earnings as well as naming having David Ricks in the company's three top positions.

I am (not for the first time) treating LLY in the current price range as a short-term momentum play that has too many issues to be a strong long term buy until the price declines.

Background

Last October 8, I wrote my first article focusing on Eli Lilly (LLY), Eli Lilly Surges On Pipeline News: Analysis And Trading Thoughts. My analysis was that the company was doing